Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119831
Chunk: 0

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 0
---
Filed Pursuant to Rule 424(b)(3)
Registration No. 333-275117

PROSPECTUS

### SCILEX HOLDING

### COMPANY
Up to 6,685,714 Shares of Common

Stock

This prospectus relates to the resale from time to time by the selling stockholder named in this prospectus (including its permitted
transferees, donees, pledgees and other successors-in-interest) (the “Selling Stockholder”) of up to an aggregate of 6,685,714 shares of our common stock, par
value $0.0001 per share (“Common Stock”), consisting of (i) up to 6,500,000 shares of Common Stock issuable upon exercise of Penny Warrants (as defined below) (such shares issuable upon exercise, the “Penny Warrant Shares”),
issued to Oramed Pharmaceuticals Inc. (“Oramed”) pursuant to the Scilex-Oramed SPA (as defined and described below) and (ii) up to 185,714 shares of Common Stock previously issued to Oramed upon exercise of a portion of the Penny
Warrants previously issued to Oramed pursuant to the Scilex-Oramed SPA (the “Issued Shares” and together with the Penny Warrant Shares, the “Resale Shares”).

On September 21, 2023 (the “Oramed Closing Date”), we entered into, and consummated the transactions contemplated by that certain
Securities Purchase Agreement, dated as of such date, between us and Oramed (the “Scilex-Oramed SPA”). Pursuant to the Scilex-Oramed SPA, among other things, on September 21, 2023, we (i) issued to Oramed (A) a senior secured
promissory note due 18 months from the date of issuance in the principal amount of $101,875,000 (the “Oramed Note”), and (B) warrants to purchase up to an aggregate of 13,000,000 shares of Common Stock, with an exercise price of $0.01
per share and restrictions on exercisability (as more fully described elsewhere in this prospectus) (collectively, the “Penny Warrants”), and (ii) caused certain outstanding warrants to purchase up to an aggregate of 114,286 shares of
Common Stock, with an exercise price of $402.50 per whole share, that we acquired